Decentralized Real-world evidence RWE data

Decentralized Clinical Trials Therapeutic Expertise

Our therapeutic expertise

With PPD™ Digital and Decentralized solutions, we strive to be at the forefront of innovation, especially when designing novel strategies to keep the patient at the center of research. Our biopharmaceutical and biotech customers trust us to help advance their critical pipelines, with our therapeutic expertise spanning the full R&D spectrum of indications.

Check out some of our recent highlights below in hematology/oncology and chronic conditions along with growing areas of R&D innovation, such as immuno-oncology, cell and gene therapy, biomarkers and rare diseases.

Ready to speak to our team about decentralized clinical trials?

Closing the gender gap in clinical research

The goal of any clinical trial is to be representative of the patient population that will need and use the medicine or device being studied. However, outdated protocols, inflexible trials designs and lagging cultural competence have resulted in women being woefully underrepresented in clinical trials.

Learn more about how our decentralized clinical trial (dct) solutions are increasing women’s participation with proven strategies to engage, recruit and retain women in clinical trials. Read the article below.

Access the article

Customized clinical trial solutions are increasing options for rare disease studies

Rare disease clinical trial sponsors turn to our full spectrum of tools, vendors, systems and platforms to produce bespoke solutions tailored to patient and research needs.

Learn how our digitally enabled and decentralized clinical trial capabilities allow high levels of study design flexibility, maximize the study quality, optimize patient participation and reach geographically distributed patient populations. Read the article below.
Access the article

Hear from a rare disease patient

Accelerating oncology clinical research remotely

As the promise of research meets the challenges of the pandemic, equipping oncology protocols with strategies to proceed safely during times of uncertainty and with reliable data quality is essential if new cancer therapeutics are to continue to reach the market.

See how our collaborators have embraced this goal and are leading the activation of remote and decentralized solutions in oncology. Read the article below.

Access the article

Minimizing patient burden in cell and gene therapy trials

Clinical trials for cell and gene therapies present a complex situation, beginning with patient recruitment and identification and continuing through implementation and long-term follow-up.

Learn how our comprehensive, patient-centric strategies create flexibility for today’s traditional trial challenges. Click below to read the article.

Access the article

Navigating the nuances of neurology clinical trials under the DCT model

With a growing need for adaptation and flexibility in neurology clinical research, study teams are finding that a hybrid approach including DTP (direct-to-patient) and DFP (direct-from-patient) modalities can significantly aid in the facilitation of clinical trials.

See how we leverage a patient-centric approach using remote monitoring, mobile technology, wearable solutions and telemedicine. Learn more, access the article below.

Access the article

How respiratory research is changing to meet the moment

Recent shifts in clinical trials investigating respiratory diseases have highlighted the importance of adaptation and evolution in clinical research, leading to a shift towards remote trial models to recruit, enroll and retain patients.

See how we are supporting the global shift towards decentralized clinical trials and balancing growing demand for technology, innovation, and risk management in respiratory studies. Read the article below.

Access the article

Modern strategies for dermatology clinical trials

We have extensive experience in dermatology and are committed to tailored trial design and digital platforms.

See how we are ideally positioned to help sponsors upgrade and modernize research options for sites and patients. Access the article below.

Access the article

Our difference

We continue to lead the way for decentralized trial strategies.